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Background: Tumor suppressor gene (TSG) inactivation plays a crucial role in carcinogenesis. FUS1, NPRL2/G21 and
RASSF1A are TSGs from LUCA region at 3p21.3, a critical chromosomal region in lung cancer development. The aim
of the study was to analyze and compare the expression levels of these 3 TSGs in NSCLC, as well as in
macroscopically unchanged lung tissue surrounding the primary lesion, and to look for the possible epigenetic
mechanism of TSG inactivation via gene promoter methylation.
Methods: Expression levels of 3 TSGs and 2 DNA methyltransferases, DNMT1 and DNMT3B, were assessed using
real-time PCR method (qPCR) in 59 primary non-small cell lung tumors and the matched macroscopically
unchanged lung tissue samples. Promoter methylation status of TSGs was analyzed using methylation-specific
PCRs (MSP method) and Methylation Index (MI) value was calculated for each gene.
Results: The expression of all three TSGs were significantly different between NSCLC subtypes: RASSF1A and FUS1
expression levels were significantly lower in squamous cell carcinoma (SCC), and NPRL2/G21 in adenocarcinoma
(AC). RASSF1A showed significantly lower expression in tumors vs macroscopically unchanged lung tissues.
Methylation frequency was 38–76 %, depending on the gene. The highest MI value was found for RASSF1A (52 %)
and the lowest for NPRL2/G21 (5 %). The simultaneous decreased expression and methylation of at least one
RASSF1A allele was observed in 71 % tumor samples. Inverse correlation between gene expression and promoter
methylation was found for FUS1 (rs = −0.41) in SCC subtype. Expression levels of DNMTs were significantly increased
in 75–92 % NSCLCs and were significantly higher in tumors than in normal lung tissue. However, no correlation
between mRNA expression levels of DNMTs and DNA methylation status of the studied TSGs was found.
Conclusions: The results indicate the potential role of the studied TSGs in the differentiation of NSCLC
histopathological subtypes. The significant differences in RASSF1A expression levels between NSCLC and
macroscopically unchanged lung tissue highlight its possible diagnostic role in lung cancer in situ recognition. High
percentage of lung tumor samples with simultaneous RASSF1A decreased expression and gene promoter
methylation indicates its epigenetic silencing. However, DNMT overexpression doesn’t seem to be a critical
determinate of its promoter hypermethylation.
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The development of non-small cell lung cancer
(NSCLC) is associated with molecular changes in more
than 20 genes localized in different chromosomal re-
gions. The most frequent molecular event in lung cancer
pathogenesis is allele loss (loss of heterozygosity, LOH)
on short arm of chromosome 3 (3p), in multiple, so
called critical regions. LOH analyses in 3p indicate two
frequently affected regions (FARs) within 3p21.3: LUCA
(lung cancer region) in the centromeric region (3p21C)
and AP20 (Alu-PCR clone 20 region) in the telomeric
region (3p21T), which contain loci of multiple tumor
suppressor genes (TSGs) [1]. Inactivation of TSGs is the
key event in carcinogenesis and involves two steps, each
of them affecting one allele. Most frequently, one TSG
allele is lost due to LOH and the other – to mutation,
or, alternatively, epigenetic inactivation via gene pro-
moter hypermethylation. The studies on LOH analysis
in lung cancer indicated that 3p allele loss is nearly
universal, shows a “discontinuous LOH pattern” in-
volving multiple, discrete sites, and appears to occur
firstly in the 600-kb 3p21.3 region [2]. The reported in-
cidence of LOH in LUCA region varied, ranging from
10 to 74 %, however, it was always higher in squamous
cell carcinoma (SCC) than in adenocarcinoma (AC),
up to 96 % and 50 %, respectively [1–3]. Additionally,
low mutation rate, below 10 %, found in lung cell lines
and primary tumors, highlighted the significance of
epigenetic modifications of TSGs in lung carcinogen-
esis [4, 5].
Epigenetic mechanisms, which include DNA methyla-
tion, post translational modifications to core histones,
microRNA (miRNA) and long non-codingRNA (lncRNA)
regulation [6], play a crucial role in regulation of gene ex-
pression by affecting chromatin accessibility. The best
known epigenetic modification in human is DNA methy-
lation. Cancer-related aberrant DNA methylation pattern,
e.g., hypermethylation of promoter sequences of TSGs,
provide a range of opportunities for risk assessment, early
detection, disease progression and prognosis, as well as
therapeutic stratification and post-therapeutic monitoring
of cancer. In lung carcinogenesis, among the potential
DNA methylation biomarkers, the hypermethylation of
APC, CDH1, CDH13, DAPK1, FHIT, MGMT, p16INK4a,
RARβ, RASSF1A, RUNX3 and SHOX2 is the most fre-
quently reported [5, 7, 8]. However, among the ever
increasing number of new studies there are also those that
negate the previous conclusions [9].
DNA methylation is an enzymatic process mediated by
DNA methyltransferases (DNMTs). DNMT1, possessing
a 7- to 21- fold preference for hemimethylated DNA
than unmethylated DNA, is the primary enzyme respon-
sible for copping methylation patterns, i.e., for its main-
tenance [10]. DNMT3 family enzymes (−3A and -3B)exhibit de novo methylation activity, as they have similar
affinities for both unmethylated and hemi-methylated
DNA substrates, and affect the methylation status of
normally unmethylated CpG sites [10]. Additionally, a
cooperation between DNMT3 family and DNMT1 has
been shown in cancer [11]. DNMTs not only play a piv-
otal role in carcinogenesis, being responsible for DNA
methylation, but also seem to be promising molecular
bio-markers for cancer diagnosis and therapy [12].
The pre-specified hypothesis tested in the study was
that the expression levels of 3 selected TSGs from
LUCA region (FUS1, NPRL2/G21 and RASSF1A) were
decreased in primary non-small cell lung cancer with
promoter hypermethylation as the responsible epigenetic
mechanism of their silencing. To investigate the factors
involved in TSG hypermethylation in NSCLC, we
attempted to determine whether DNMT1 and DNMT3B
RNA expression levels correlated with the hypermethyla-
tion of the promoters of the studied tumor suppressor
genes. We tried to elucidate the role of the studied TSGs
in early lung carcinogenesis and cancer progression.
Materials and methods
The study has been approved by the Ethical Committee
of the Medical University of Lodz, Poland, no. RNN/
140/10/KE. Written informed consent was obtained
from each patient.
Characterization of the lung tissue samples and patients
clinical characteristics
The study involved the group of 59 patients with diag-
nosis of NSCLC, treated in the University Clinic of
Pneumology and Allergology of Ist Chair of Internal
Diseases of Medical University of Lodz and in the
Department of Thoracic Surgery, General and Oncologic
Surgery, Medical University of Lodz, Poland, between July
2010 – March 2013. In NSCLC patients, during the
planned surgery (lobectomy or pneumonectomy), tissue
fragments (100–150 mg) were obtained from the center of
primary lesion and the adjacent noncancerous (10 cm
distant from the primary lesion), macroscopically un-
changed tissue (conventional “normal” sample). Immedi-
ately after resection, lung tissue samples were placed in a
stabilization buffer RNAlater®. Each tissue sample was di-
vided into smaller parts (30–50 mg) for individual ana-
lysis, and frozen at −80 °C.
The resected tissue samples were post-operatively
histhopathologically evaluated and classified according
to the AJCC staging as well as TNM classification
(pTNM). Based on histopathological assessments, the
group of patients was subdivided in relation to NSCLC
subtypes, i.e., squamous cell carcinoma (SCC), adenocar-
cinoma (AC) and large cell carcinoma (LCC). Relevant
clinical and pathological characteristics of the patients
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Table 1. All cases were primary tumors without chemo-
or radiotherapy treatment.
The design of our study assumed the analysis of gene
expression in two study groups: the tumor and the sur-
rounding normal lung tissue, to compare the both type
of tissue. The more so, because there are reports indicat-
ing no significant differences between cancerous and
non-cancerous tissue in regard to some TSG expression
[13]. On the other hand, accumulating evidence point to
genetic/epigenetic changes occurring in normal tissue
adjacent to tumor (the so called “field cancerization”
process), which are widely described in literature in vari-
ous cancer types and highlights the importance of early
abnormalities in carcinogenesis [14, 15].
RNA extraction, real-time PCR (qPCR method)
Total RNA was extracted from primary lung cancer and
macroscopically unchanged lung tissues, using Universal
RNA Purification Kit (Eurx, Poland), according to the
manufacturer’s recommendations. The qualitative and
quantitative assessments of RNA samples were deter-
mined using RNA 6000 Pico/Nano LabChip kit
(Agilent Technologies, USA) in Agilent 2100 Bioanalyzer
(Agilent, USA).
Complementary DNA (cDNA) was transcribed from
100 ng of total RNA, using a High-Capacity cDNATable 1 Clinicopathological features of the studied NSCLC group
Analyzed variables NSCL
Gender (n, %) Wom
Men
Age (n, %) Mean




Histopathological type of NSCLC (n, %) SCC (
NSCC
AJCC classificationb (n, %) I (11,
II (21,
III (27
Tumor size according to pTNM classificationc (n, %) T1 (1
T2 (3
T3/T4
aPYs were calculated according to the NCI Dictionary of Cancer Terms: 1 Pack Year
(http://www.cancer.gov/dictionary?CdrID=306)
bAJCC – American Joint Committee on Cancer Staging according to the IASCLC Sta
cpTNM – post-operative Tumor Node Metastasis classification according to the WHOReverse Transcription Kit (Applied Biosystems, USA).
Reverse transcription (RT) master mix contained: 10x
RT buffer, 25x dNTP Mix (100 mM), 10x RT Random
Primers, MultiScribe™ Reverse Transcriptase, RNase In-
hibitor and nuclease-free water, in a total volume of
20 μl. RT reactions were performed in the following
conditions: 10 min at 25 °C, 120 min at 37 °C, then 5 s
at 85 °C for, and 4 °C hold.
The relative expression of the studied genes was
assessed in qPCRs using Micro Fluidic Cards, the so
called TLDA (TaqMan® Low Density Custom Arrays)
plates, with pre-loaded selected assays (Applied Biosys-
tems, USA): FUS1-Hs00200725_m1, NPRL2/G21-
Hs00198012_m1, RASSF1A-Hs00200394_m1, DNMT1-
Hs00945875_m1, DNMT3B-Hs00171876_m1. ESD
(Hs00382667_m1) was used as a reference gene and
RNA isolated from normal lung tissue (Human Lung
Total RNA, Ambion®, USA) served as calibrator samples.
All qPCRs were performed using 7900HT Fast Real-
Time PCR System (Applied Biosystems, USA) with RQ
software (TaqMan Relative Quantification Assay soft-
ware). The reaction mixture contained: 50 μl cDNA
(50 ng) and 50 μl TaqMan® Universal Master Mix
(Applied Biosystems, USA). The PCR program was as
follows: initial incubation 2 min at 50 °C, AmpliTaq
Gold® DNA polymerase activation at 94.5 °C for 10 min,
then 40 two-step cycles 30 s at 97 °C and 60 s at 59.7 °C.C patients
en (24, 41 %)
(35, 59 %)
61 ± 7.62 ≤60 yrs (14, 24 %)
61-70 yrs (30, 51 %)
>70 yrs (15, 25 %)
ers (54, 92 %) <40 Pack Yearsa (PYs) (26, 48 %)
nt smokers (31, 57 %)
r smokers (23, 43 %) ≥40 PYs (28, 52 %)
mokers (5, 8 %)
34, 58 %)
(25, 42 %) AC (20, 80 %)







is equal to 20 cigarettes smoked per day for 1 year
ging Project 7th ed. (2010) Cancer
Histological Typing of Lung Tumor
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methylation-specific PCRs (MSP method)
The extraction of genomic DNA from NSCLC speci-
mens was performed using a QIAamp DNA Mini Kit
(Qiagen, Germany), according to the manufacturer’s
protocol. To obtain RNA-free genomic DNA, RNase A
(100 mg/ml) was used as optionally indicated in the kit
procedure. The quality and quantity of DNA was
spectrophotometrically assessed, measuring absorb-
ance at 260/280 nm (Eppendorf BioPhotometer™ plus,
Germany). DNA samples with a 260/280 nm ratio in
the range 1.8–2.0 were considered as high quality and
selected for further analysis.
Genomic DNA (1 μg) was modified with sodium bisul-
fite, using the CpGenomeTM Turbo Bisulfide Modifica-
tion Kit (CHEMICON International, Millipore, USA),
according to the manufacturer’s protocol. Its concentra-
tion and purity was spectrophotometrically estimated
(Eppendorf BioPhotometer™ plus, Germany).
Bisulfite converted DNA was used for methylation-
specific polymerase chain reactions (MSPs) to assess
methylation status of the studied genes. Primers for
MSPs were designed according to the criteria described
by Feltus et al. [16], using computer tool (methPrimer
v1.1 beta, Li Lab, Department of Urology, USCF) [17].
The set of primers for the studied genes were flanking
the 1 kb 5′ region upstream from the translation start
point Primer sequences for methylated and unmethy-
lated promoter regions of the studied genes are included
in Table 2. MSP master mix contained: 1000 ng DNA,
0.7 μM of each primer (Sigma-Aldrich, Germany),
2.5 μM dNTPs mix, 2.5 μM MgCl2, Hot Start AmpliTaq
Gold® 360 DNA Polymerase (5U/μl), 10x Universal PCR
buffer and nuclease-free water, in a total volume of
12.5 μl. PCR conditions were as follows: initial denatur-
ation at 95 °C for 5 min, followed by 40 three-step cycles
involving denaturation at 95 °C for 45 s, specific anneal-
ing temperature – (see Table 2) – for 45 s and elong-
ation at 72 °C for 1 min; the final elongation step was
done at 72 °C for 10 min. The annealing temperatures
for each MSP primer were experimentally determined in
a set of gradient PCRs. The range of temperatures tested,Table 2 Characterization of MSP primers (M – methylated; U – unm
forward and reverse primers indicate the presence of methylated cy
Gene Forward primer Primer position Reverse
FUS1 M: TGTTATCGTGGATTAGATATTGTTC −559 to −482 M: ACT
U: TTATTGTGGATTAGATATTGTTTGT −557 to −480 U: ACT
NPRL2/G21 M: GTTCGGTTATTGTTATGGGTAGC +108 to +131 M: AAC
U: GGTTTGGTTATTGTTATGGGTAGTG +107 to +132 U: ACC
RASSF1A M: ATATTTTTTCGATTTGGAGTTTTTTC −599 to −573 M: CTA
U: TTTTTTTGATTTGGAGTTTTTTTGT −599 to −573 U: TACcovering these given in individual primer specifications
(Sigma-Aldrich, Germany) were as follows: 50.5–60.5 °C
for FUS1, 52.5–64.2 °C for NPRL2/G21, and 53–66.5 °C
for RASSF1A.
Positive and negative MSP controls were included in
each PCR reaction. CpGenome Universal Methylated
DNA (enzymatically methylated human male genomic
DNA) served as a positive methylation control and
CpGenome Universal Unmethylated DNA (human fetal
cell line) was used as a negative control (CHEMICON
International, Millipore, USA). As a control for PCR
contamination, blank samples with nuclease-free water
instead of DNA were used.
The MSP products were electrophoretically separated
on 2 % agarose gel and concentrations (ng) of MSP
products (U and M DNA alleles) were spectrophotomet-
rically estimated, using DNA1000 LabChip Kit, on
Agilent 2100 Bioanalyzer (Agilent Technologies, USA).
For each sample, Methylation Index (MI) was assessed
using the following formula: peak height of methylated
products/(peak height of methylated products + peak
height of unmethylated product), MI = (M)/(M +U).
Statistical analysis
The results of relative expression analysis (RQ values)
are presented as medians in each studied group. The
comparison of RQ values between cancer and non-
cancer specimens was performed using Mann–Whitney
U test and Kruskal-Wallis test. The same nonparametric
tests were applied to compare the differential expressions
and methylation status of TSGs between NSCLC sub-
types, i.e., SCC, AC and LCC. Spearman’s rank correlation
coefficient, Mann–Whitney U test and Kruskal-Wallis test
were performed to evaluate the relationship between gene
expression and methylation levels and clinicopathological
parameters (patients’ characteristics: age, gender, history
of smoking and tumor staging according to pTNM and
AJCC classifications). The Newman–Keuls method was
used to identify significantly different samples, regarding
gene expression and methylation levels. Nonparametric
Spearman’s criterion was used to calculate the coefficient
of correlation between the levels of mRNA expression orethylated) used in the study. The underlined nucleotides in







ATATTTTTACGATTACCACGCT −375 to −349 207 56.5
ATATTTTTACAATTACCACACT −375 to −349 205 56.5
CAATTAAACTCTCGAAAACGT +238 to +261 153 52.5
AATTAAACTCTCAAAAACATC +238 to +261 153 56.5
CACTATAACCTACCCATCCTCG −409 to – 384 215 56.5
ACTATAACCTACCCATCCTCAC −410 to −385 211 57.5
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pairs with methyltransferases. Receiver operating charac-
teristic (ROC) curve was established to discriminate
NSCLC and adjacent normal tissue.
P-values < 0.05 were considered statistically significant.
All statistical procedures were performed using Statistica
for Windows 10.0 software.
Results
Relative expression levels of the studied TSGs
Relative expression levels of the studied tumor suppres-
sor genes in NSCLC and macroscopically unchanged
lung tissue samples were determined using delta-delta
CT method, and expressed as RQ values adjusted to the
expression of ESD (endogenous control) and in relation
to the expression level of calibrator (normal lung tissue),
for which RQ = 1.
The obtained RQ values, for the studied TSGs in indi-
vidual NSCLC samples, are presented in Fig. 1. The sim-
ultaneous down regulation of all 3 TSGs was found only
in 5.9 % specimens. Simultaneous decreased expressionFig. 1 Relative expression levels of the three TSGs, presented as log2RQ, inof RASSF1A and FUS1 was observed in 23.5 % SCC
samples, and paired RASSF1A and NPRL2/G21 were
simultaneously decreased in 20.9 % SCC and 16 %
NSCC samples. Generally, RASSF1A gene showed
decreased expression in the majority of lung tumors
(especially in SCC subtype), while the expression levels
of NPRL2/G21 and FUS1 in most cases were similar to
the level of calibrator. Table 3 shows the frequency of
NSCLC samples with importantly decreased expression.
The obtained RQ values were correlated with histo-
pathological NSCLC subtypes (SCC, AC, LCC), tumor
staging (pTNM, AJCC), patients’ age, gender and smok-
ing history, as well as with RQ values of the studied
genes in macroscopically unchanged lung tissue samples.
Additionally, correlations between all studied genes were
analyzed.
Comparing NSCLC histolopathological subtypes, the
expression levels of RASSF1A and FUS1 were significantly
different, while in case of NPRL2/G21 gene, only a ten-
dency was observed. Regarding patients’ age, NPRL2/G21
showed significantly lower expression in older patients.the studied NSCLC histopathological subtypes
Table 3 Frequency of importantly decreased TSG expression
(RQ < 0.5)
Gene NSCLC samples (T) Paired “normal” samples (N)
Total SCC NSCC Total SCC NSCC
(n = 59) (n = 34) (n = 25) (n = 59) (n = 34) (n = 25)
RASSF1A 23.7 % 29.4 % 16 % 5.1 % 2.9 % 8 %
(n = 14) (n = 10) (n = 4) (n = 3) (n = 1) (n = 2)
NPRL2/G21 5.1 % 2.9 % 8 % 3.4 % 2.9 % 4 %
(n = 3) (n = 1) (n = 2) (n = 2) (n = 1) (n = 1)
FUS1 0 % 0 % 0 % 1.7 % 2.9 % 0 %
(n = 0) (n = 0) (n = 0) (n = 1) (n = 1) (n = 0)
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lower expression level in females in NSCC group, and sig-
nificantly lower expression in males in SCC group. In rela-
tion to tumor size (pTNM classification), RASSF1A
expression was the lowest in T2 group in total NSCLC
group, and similarly in NSCC subgroup. Regarding AJCC
classification, statistically significant differences were
observed for FUS1 gene in NSCC subtype. Comparing
tumor and macroscopically unchanged lung tissue sam-
ples, statistically significant differences were found for all
genes, however only in case of RASSF1A gene its expres-
sion level was significantly lower in tumors. No significant
differences were observed in correlation with cigarette
smoking. The results are summarized in Table 4.
Newman-Keuls test documented statistical significances
between the expression levels of the studied genes in pairs
in NSCLC group, as well as in NSCLC histopathological
subtypes: statistically significant differences were found
between RASSF1A vs NPRL2/G21 (P = 0.001) and
RASSF1A vs FUS1 (P = 0.00002) in total study group,
and similarly in SCC subtype, where significant differences
were found between RASSF1A vs NPRL2/G21 (P = 0.001)
and RASSF1A vs FUS1 (P = 0.0003); in AC and NSCC
subtypes, the expression levels of RASSF1A and FUS1A
were significantly different (P = 0.03 and P = 0.005, re-
spectively). In all mentioned cases, RASSF1A expression
level was significantly lower than those of the other genes.
Spearman’s rank correlation coefficient revealed positive
correlations between genes: RASSF1A and NPRL2/G21
(P = 0.0001, rs = 0.38), RASSF1A and FUS1 (P = 0.001,
rs = 0.34) in NSCLC group; and also between RASSF1A
and NPRL2/G21 in AC (P = 0.02, rs = 0.52) and NSCC
(P = 0.002, rs = 0.60) group.
ROC curve analysis of RASSF1A expression level as a
marker to distinguish NSCLC tissue from macroscopically
unchanged lung tissue demonstrated a sensitivity of 61 %,
specificity of 73 % and accuracy of 67 % (AUC= 0.695).
Additionally, we analyzed the utility of RASSF1A and
FUS1 as potential markers distinguishing NSCLC histo-
pathological subtypes: NSCC and SCC. Analyzed together,the genes yielded a sensitivity of 69 %, specificity of 66 %
and accuracy of 68 % (AUC = 0.714). Separately, ROC
curve analysis illustrated for RASSF1A: a sensitivity of
79 %, specificity of 64 % and accuracy of 73 % (AUC=
0.729); and for FUS1: a sensitivity of 88 %, specificity of
56 % and accuracy of 74 % (AUC= 0.729).
Relative expression levels of the studied DNMTs
Relative expression of two DNA methyltransferases,
DNMT1 and DNMT3b, were also analyzed on mRNA
level. The expression levels of both DNMTs were in-
creased in tumor samples: median RQ value for
DNMT3B was 3.81 and for DNMT1 1.38. Regarding the
frequency of samples with increased DNMT expression,
DNMT1 was overexpressed in 75 % NSCLCs (68 % SCC,
76 % NSCC) and DNMT3B in 92 % NSCLCs (91 % SCC,
92 % NSCC).
Correlations were analyzed between the expression
levels of the studied DNMTs and histopathological
NSCLC subtypes (SCC, AC, LCC), tumor staging
(pTNM, AJCC), patients’ age, gender and smoking his-
tory, as well as in relation to RQ values of the studied
DNMTs found in macroscopically unchanged lung tissue
samples. DNMT3B expression level was significantly
higher in younger patients (≤60 vs 61–70 years old)
in AC subtype (7.14 vs 2.43, P = 0.04, Mann–Whitney
U-test) and in NSCC subtype (7.37 vs 2.43, P = 0.006,
Mann–Whitney U-test), where also the negative cor-
relation was observed (rs = −0.50, P = 0.01, Spearman’s
rank correlation coefficient). No statistically signifi-
cant differences were found in relation to patients’
gender and smoking, or tumor size (pTNM classification)
and grade (AJCC classification). However, in SCC group
DNMT1 revealed a trend (P = 0.05, Mann–Whitney U-
test) toward higher expression in grade I/II vs grade III
tumors (1.53 vs 1.10).
The expression levels of both DNMTs were significantly
higher in tumors when compared with macroscopically
unchanged lung tissue samples, in total NSCLC group
and in NSCLC histopathological subgroups, as shown in
Table 5.
Additionally, the expression levels of the studied DNA
methyltransferases were positively correlated (Spearman’s
rank correlation coefficient) in all tissue groups: in total
NSCLC cohort (rs = 0.51, P = 0.0001), in SCC (rs = 0.51,
P = 0.002), in AC (rs = 0.49, P = 0.03), in NSCC (rs = 0.55,
P = 0.004).
There weren’t any negative correlations between the
levels of expression of the methyltransferases and TSGs.
Methylation status of the studied TSG genes: the
qualitative and quantitative assessments
The results on methylation status of the studied genes
were obtained for different numbers of patients, due to
Table 4 Correlations analyzed between the expression levels of the studied genes and tumor clinicopathological parameters and
patients’ characteristics
FUS1 (n = 59) NPRL2/G21 (n = 59) RASSF1A (n = 59)
Median RQ in NSCLC samples
1.35 1.36 0.77
SCC vs AC vs LCC
1.18 vs 1.83 vs 2.39 P = 0.002a 1.28 vs 1.79 vs 0.83 P = 0.05a 0.68 vs 1.01 vs 0.86 P = 0.01a
SCC vs AC
1.18 vs 1.83 P = 0.004b 1.28 vs 1.84 P = 0.03b 0.68 vs 1.01 P = 0.002b
SCC vs NSCC
1.18 vs 2.13 P = 0.001b P > 0.05 0.68 vs 1.01 P = 0.002b
Age (≤60 yrs vs 61–70 yrs vs >70 yrs) – in total NSCLC group; in NSCLC histopathological subgroups
P > 0.05 In SCC: 61–70 yrs vs >70 yrs P > 0.05
1.55 vs 0.99 P = 0.001b
Gender (females vs males) – in total NSCLC group; in NSCLC histopathological subgroups
P > 0.05 P > 0.05 In SCC: 1.04 vs 0.64 P = 0.02b;
in AC: 0.86 vs 1.31 P = 0.01b;
in NSCC: 0.86 vs 1.31 P = 0.02b
pTNM classification (T1 vs T2 vs T3/4) – in total NSCLC group; in NSCLC histopathological subgroups
P > 0.05 P > 0.05 0.80 vs 0.67 vs 0.94 P = 0.04a;
T2 vs T3/4 P = 0.01b;
in NSCC: 1.35 vs 0.75 vs 1.27 P = 0.04a; T2 vs T3/4 P = 0.04b
AJCC classification (I vs II vs III) – in total NSCLC group; in NSCLC histopathological subgroups
In NSCC: 2.44 vs 1.20 vs 2.25 P = 0.04a; I vs II P = 0.02b P > 0.05 P > 0.05
Smoking status (current smokers vs former smokers vs never smokers) – in total NSCLC group; in NSCLC histopathological subgroups
P > 0.05 P > 0.05 P > 0.05
Smoking history (PYs: <40 vs ≥40) – in total NSCLC group; in NSCLC histopathological subgroups
P > 0.05 P > 0.05 P > 0.05
Tumor (T) tissue vs macroscopically unchanged lung tissue – in total NSCLC group; in NSCLC histopathological subgroups
in AC: 1.83 vs 1.18 P = 0.01b; 1.36 vs 0.84 P = 0.0003b; 0.77 vs 1.07 P = 0.0003b;
in NSCC: 2.13 vs 1.20 P = 0.002b in SCC: 1.28 vs 0.84 P = 0.01b; in SCC: 0.68 vs 1.09 P = 0.000002b
in AC: 1.84 vs 0.84 P = 0.002b;
in NSCC: 1.79 vs 0.84 P = 0.009b
aKruskal-Wallis test; bMann–Whitney U-test
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RASSF1A, 3 in cases of NPRL2/G21 and FUS1.
Promoter methylation analysis of the studied genes, per-
formed as MSP reactions, distinguished unmethylated (U)
from methylated (M) DNA alleles after electrophoretic
separation. Both U and M alleles were found in all studied
tumor tissue groups. Next, based on spectrophotometricTable 5 RQ values (medians) correlated between tumor vs macrosc
(Mann–Whitney U-test)
Gene total NSCLC group SCC subgroup
DNMT1 1.38 vs 0.71 P = 0.0001 1.36 vs 0.69 P = 0.00
DNMT3B 3.81 vs 1.63 P = 0.0001 5.24 vs 1.61 P = 0.00estimation (Agilent 2100 Bioanalyzer), fluorescence units
(FU) of MSP products were quantified (ng/μl), according
to DNA size marker (DNA ladder, Agilent Technologies,
USA) and Methylation Index (MI) was calculated for each
gene in all tissue samples.
The MSP reactions revealed the presence of M alleles
for all genes, in 38–76 % samples, depending on theopically unchanged lung tissue samples, with P value
AC subgroup NSCC subgroup
01 1.57 vs 0.74 P = 0.0001 1.38 vs 0.73 P = 0.0002
01 3.63 vs 1.72 P = 0.002 3.57 vs 1.64 P = 0.001
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alleles of all studied TSGs, are shown in Fig. 2. The
highest frequency of both methylated alleles was
observed for RASSF1A gene (20 %) and the same gene
revealed the lowest number of samples with no methyl-
ated alleles (4 %). Generally, the most abundant were
samples with the presence of both methylated and
unmethylated alleles (38–76 %, depending on the gene).
The calculated MIs indicated gene methylation level,
which in tumor samples ranged from 3 to 66 %, depend-
ing on the gene. Among the studied genes, RASSF1A
showed the highest methylation level: 52 % in total
NSCLC group, 50 % in SCC, and 66 % in AC; NPRL2/
G21 – the lowest: 5 % in total NSCLC group, 3 % in
SCC, and 10 % in AC. Methylation level of FUS1 was
17 % in total NSCLC group, also 17 % in SCC and 10 %
in AC.
Statistical analysis (Newman-Keuls test) revealed signifi-
cantly higher methylation status of RASSF1A than those
of other studied genes in all tissue groups. In NSCLC:
RASSF1A vs FUS1 (P = 0.0001), RASSF1A vs NPRL2/G21
(P = 0.00002); MI values of FUS1 were also significantly
higher than NPRL2 methylation status (P = 0.01) in this
tissue group. The results are shown in Fig. 3. Similarly in
SCC group: RASSF1A vs NPRL2/G21 (P = 0.00002),
RASSF1A vs FUS1 (P = 0.0001); and also FUS1 vs NPRL2/
G21 (P = 0.04). In AC: RASSF1A vs NPRL2/G21 (P =
0.0001), RASSF1A vs FUS1 (P = 0.0001).Fig. 2 The frequencies of methylated (M) and unmethylated (U) alleles of tConcerning tumor histopathological characteristics, in
SCC group FUS1 was significantly higher methylated in
stage II vs stage III tumors (P = 0.03, Mann–Whitney
U test). No other significant correlations were found
between gene methylation and clinicopathological
parameters.
Correlation between gene expression level and
methylation status
The decreased expression of RASSF1A was accompanied
by promoter methylation in 71 % NSCLC samples, in case
of FUS1 it was found in 20 % NSCLC specimens, and only
in 5 % NSCLC samples for NPRL2/G21. Statistical analysis
revealed the negative correlation between the RQ and MI
values for only one gene, FUS1 (P = 0.02, Spearman’s rank
correlation coefficient, rs = −0.41) in SCC subtype.
Spearman’s rank correlation coefficient didn’t reveal
statistically significant correlations between TSG methy-
lation and DNMT expression (P > 0.05).
Discussion
The aim of our study was to analyze by qPCR and com-
pare the expression levels of 3p TSGs in non-small cell
lung cancer samples, as well as in macroscopically un-
changed tissue surrounding the primary lesion. To look
for the possible epigenetic mechanism of TSG inactiva-
tion, gene promoter methylation was assessed, as well as
the levels of DNMT1 and DNMT3B RNA expression.he studied genes, based on MI values
Fig. 3 Box and whisker plot representing mean MI values of the studied genes in NSCLC group
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performed to compare expression of several 3p TSGs in
the same lung tumor samples [18–22]. In order to inves-
tigate it further we chose 3 TSGs and analyzed their
expression in lung primary tumors: non-small cell lung
cancer (NSCLC), adenocarcinoma (AC), squamous cell
lung cancer (SCC) and large cell cancer (LCC). Similarly,
few studies have focused so far on simultaneous analysis
of methylation status of more than two genes at 3p21.3
locus in primary lung cancer [21, 23, 24].
The chosen TSGs, namely FUS1, NPRL2/G21 and
RASSF1A, are located in proximity, in 3p21.3 subregion
called LUCA. Such close position could suggest the ten-
dency toward simultaneous decrease of their expression.
However, this was not the case in our study. Only few
tumor samples showed decreased expression of all three
genes. The low levels of promoter methylation of
NPRL2/G21 and, to some extent, of FUS1 also didn’t
designate their epigenetic inactivation in the population
studied.
The highest frequency of decreased expression and in-
creased promoter methylation we found for RASSF1A
gene. The simultaneous decreased expression and
methylation of at least one RASSF1A allele was found in
71 % tumor samples. Tumor suppressor gene, RASSF1A
(Ras association domain family member 1), is involved
in development or progression in the vast majority of
cancers [4, 25, 26]. In NSCLC, RASSF1A decreased ex-
pression was found in 67 % samples, as reported by
Senchenko et al. [21], although it is usually reported at
the level of about 30 % [27]. In our study we confirmed
decreased expression of RASSF1A (RQ < 1), and theimportant gene downregulation (RQ < 0.5) was observed
in more than 20 % of NSCLC samples, with higher fre-
quency in SCC group (reaching nearly 30 %). In paired
“normal” lung tissue specimens RASSF1A decreased
expression was found only in 3–8 % samples. The differ-
ences between the studied groups, i.e., between NSCLC
subtypes and between primary tumor specimens and the
surrounding macroscopically unchanged lung tissue
samples, were statistically significant (in total study
group and in SCC subtype). The highest RASSF1A ex-
pression level – similar to that observed in “normal”
lung tissue – was found in AC group. Similarly, the in-
creased level of RASSF1A mRNA in lung cancer was also
observed by others, who found even 3-to-4 fold increase
in AC subtype [21]. RASSF1A gene – as the only one in
our analysis – revealed correlations with gender: signifi-
cantly lower gene expression was found in men in SCC
group and in women in NSCC group. Regarding TNM
classification, significantly lower RASSF1A expression
was observed in T2 tumors as compared with T3/4
NSCLC. It could confirm its role at earlier stages of lung
carcinogenesis. However, in other studies, no statistically
significant differences were observed with relation to
age, smoking history and other cytological and patho-
logical characteristics [21].
Significant differences found between tumor and
“normal” lung samples indicate the possible clinical util-
ity of RASSF1A gene expression level as a diagnostic
marker. In most studies, the principal cause of RASSF1A
loss of expression was tumor-specific RASSF1A promoter
hypermethylation, while tumor-associated mutations were
rare [25, 26, 28]. In our study, the frequency of RASSF1A
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gene methylation level was equal to or exceeded 50 %, de-
pending on the histotype. The observed methylation fre-
quency of RASSF1A was in the top of the reported by
others 26–87 % range [23, 25, 29–34].
In several reports, RASSF1A methylation was associated
with poor prognosis in NSCLC patients [30–32, 35]. We
didn’t observe any associations with tumor clinicopatho-
logical features, such as TNM or AJCC staging, or pa-
tients’ smoking habits. Similar results were obtained by
others [34, 35]. Meta-analysis performed in 2013 con-
firmed a significant association between RASSF1A methy-
lation and NSCLC, however there were no significant
differences in RASSF1A methylation in relation to gender,
pathology, TNM stage and smoking behavior among
NSCLC cases [36].
It is true that of all the genes in the 3p21.3 critical
region RASSF1 has been the most comprehensively stud-
ied at the genetic, epigenetic and functional level, and its
role as a tumor suppressor gene has been proven. How-
ever, the results regarding the utility of RASSF1A epigen-
etic inactivation as a prognostic marker in NSCLC are
still divergent [9, 27, 31, 33]. In our study, RASSF1A
methylation level was significantly higher than that of
other studied genes, however, lack of any other associa-
tions does not entitle us to decisive conclusions.
Another gene localized in LUCA region, FUS1 (fused
in sarcoma), also known as TUSC2 (tumor suppressor
candidate 2) is recently identified TSG, involved in
apoptosis. Loss or reduction of FUS1 protein expression,
associated with poorer prognosis, was observed in lung
cancers [37–39]. We didn’t observe importantly decreased
expression of FUS1 on mRNA level in lung tumor sam-
ples. Statistically significant differences between NSCLC
histotypes and the lowest gene expression level in SCC
might suggest FUS1 significance predominantly in squa-
mous cell carcinoma. In NSCC subtype, significantly de-
creased FUS1expression in stage II vs stage III tumors
could indicate its role at early stage of carcinogenesis.
However, generally, FUS1 expression level was similar to
that observed for calibrator, i.e., normal lung tissue. No
aberrant FUS1 mRNA level was also found by other re-
searchers [28]. FUS1 promoter methylation analysis in our
study revealed the presence of methylated alleles in 58 %
NSCLC samples and rather moderate gene methylation
status, ranging from 10 to 22 %, depending on histopatho-
logical subtype. However, as the only gene in our analysis,
FUS1 revealed negative correlation between its expression
level and methylation status. Additionally, significantly
higher gene promoter methylation level in II vs III tumors
in SCC subgroup might support FUS1 possible role at
early stage of lung cancer development.
So far, there have not been published any reports on
FUS1 promoter hypermethylation in lung cancer, althoughit was found to be partially methylated in head and neck
squamous cell carcinoma [40]. Little is known on molecu-
lar mechanisms involved in the regulation of FUS1
expression in primary lung cancer cells. FUS1 mRNA
transcripts were found in both normal lung and some lung
cancer cell lines, but FUS1 protein was absent in a major-
ity of lung cancer cell lines and NSCLC samples [38]. Re-
searchers indicate the role of 3'-untranslated regions
(UTRs) of the FUS1 gene transcript [41] or the influence
of another epigenetic mechanisms, e.g., the role of several
miRNAs in the down-regulation of FUS1 protein expres-
sion in lung cancer cells [42] or aberrant histone modifica-
tions [43]. Thus, the inactivation of FUS1 may occur
through abnormal translational control of FUS1 mRNA or
aberrant post-translational protein modification resulting
in its inactivation despite the absence of mutations and in
the presence of high levels of transcript mRNA [44].
The physiological role of FUS1 is still poorly known
and further investigation of this interesting TSG in lung
cancer is required.
NPRL2/G21 (nitrogen permease regulator-like 2 gene),
also known as TUSC4 (tumour-suppressor candidate 4),
is a tumor suppressor gene commonly expressed in nor-
mal tissues, including lung tissue. The study results indi-
cate that NPRL2/G21 is involved in DNA repair, cell
cycle control and apoptosis [45]. Senchenko et al. [21]
showed significantly decreased gene expression level in
73 % NSCLC cases, but the earlier report described nor-
mal NPRL2/21 mRNA expression in most lung cancers
[25]. Stop mutations, nonsense deletions and missense
mutations were found in this gene [18, 45]. Epigenetic
analyses failed to show gene promoter hypermethylation
in cancer cell lines [43, 45], and no such studies have
been performed so far in primary lung tumors.
In our study, we didn’t confirm decreased expression
of NPRL2/G21 in lung tumor samples. However, the dif-
ferences between NSCLC histopathological subtypes
were significant, with lower expression level in SCC
samples. Although, it was still at the level of calibrator
(normal lung tissue). In some studies, increased expres-
sion of NPRL2/G21 on mRNA or protein level was also
observed [21, 46]. Interestingly, NPRL2/G21 gene – as
the only TSG in our study group – showed correlation
with age: in SCC samples its expression level was signifi-
cantly lower in elder patients (>70 years old).
The exact mechanism involved in the possible inacti-
vation of NPRL2/G21 in human cancers has not been
elucidated. In our study we didn’t observe hypermethyla-
tion of NPRL2/G21 promoter region. The frequency of
gene methylation in NSCLC samples was very low and
its methylation status was significantly lower than that
of other studied TSGs.
According to the results obtained by Lerman & Minna
[28], NPRL2/G21 may be one of the haploinsufficient
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and do not show a second mutation – or promoter
hypermethylation – in the other allele (wild-type allele).
Alternatively, as in the case of other 3p21.3 tumor
suppressors, like RASSF1A and FUS1, such mechanisms
as chromosome instability, aneuploidy, altered RNA
splicing, or defects in transcriptional, translational, and
posttranslational modifications that are common in the
3p region, may play a role in the inactivation of NPRL1/
G21 in lung tumors.
Although the function of NPRL2/G21 is still unknown,
it revealed interesting association in lung cancer: gene
decreased expression was conversely correlated with cis-
platin sensitivity in NSCLC cell lines [46]. This finding,
of significant clinical value, could indicate the possible
therapeutic role of NPRL2/G21 for enhancing and
re-sensitizing non-responders to cisplatin. Therefore,
NPRL2/G21 deserves attention and further study in
lung cancers, regarding its expression and underlying
mechanisms of its possible silencing.
None of the genes revealed correlations with smoking
history. It is in accordance with the results of Senchenko
et al. [21]. Although smoking is a known risk factor in
NSCLC, the lack of correlations with expression levels
and methylation status of the studied TSGs could indi-
cate that tobacco smoke targets other than studied
genes.
We tested whether the methylation status of tumor
suppressor genes was associated with the mRNA expres-
sion levels of DNA methyltransferases (DNMTs). The
role of DNMT mediated epigenetic alterations in lung
cancer development has been the focus of increasing
interest in recent years. In our study both enzymes were
highly expressed in a coordinate manner in lung tumors –
positive correlation was observed in all NSCLC histo-
pathological types, as well as in total NSCLC group. In
case of both studied DNMTs, we found significantly
higher expression levels in lung tumor specimens as com-
pared with macroscopically unchanged tissue samples.
Regarding NSCLC histopathological subtypes, DNMT3B
expression was higher in SCC than in NSCC, although it
didn’t reach statistical significance. DNMT1 revealed trend
toward higher expression in grade I/II tumors in SCC
group, suggesting its role at early stages of lung carcino-
genesis. However, in other studies, deregulated expression
of DNMT1 was an independent prognostic factor in SCC
[47, 48]. Interestingly, in AC and NSCC subtypes,
DNMT3B expression levels were significantly higher in
patients aged 60 and below as compared with older pa-
tients. Elevated DNMT expression in younger patients
was more frequent also in other study [48].
We didn’t observe any negative correlations between
the expression levels of the studied TSGs and methyl-
transferases. The results of others are also conflicting.Similarly to our findings, the elevated mRNA levels of
DNMT1 and DNMT3B were not significantly associated
with hypermethylation of the several TSGs, including
RASSF1A, in lung cancer cell lines [49] and in lung
primary tumors [48, 50]. Others found correlations
between TSG promoter hypermethylation and DNMT
overexpression, but on protein level [47]. Overexpres-
sion of DNMT was found to occur earlier than the
methylation modifications and complex interactions be-
tween several factors in hypermethylation process was
highlighted [48, 50]. So, there is still a need to elucidate
the clinicopathological significance of DNA methyltrans-
ferases in primary non-small cell lung cancer.
Conclusions
The results of our study indicate the potential role of
the studied genes in the differentiation of NSCLC histo-
pathological subtypes: RASSF1A and FUS1 could be
regarded as markers differentiating SCC and NSCC, as
their expression levels were significantly lower in squa-
mous cell carcinoma subtype; similar role could be
assign to NPRL2/G21 in differentiating SCC and AC
subtypes. Although, the most prominent role was docu-
mented in case of RASSF1A. The significant differences
in its expression level between NSCLC and macroscop-
ically unchanged lung tissue surrounding the primary le-
sions highlight its possible diagnostic role in lung cancer
in situ recognition. High percentage of lung tumor sam-
ples with simultaneous RASSF1A decreased expression
and gene promoter methylation indicates its epigenetic
silencing. However, overexpression of methylating enzymes
(DNMT1 and DNMT3B) enzymes was not a critical deter-
minate of tumor-specific promoter hypermethylation of
RASSF1A and FUS1, which revealed, respectively, high and
moderate methylation frequency in our study.
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